Related Experiment Video
Updated: Jul 22, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
[Radiotherapy in multiple modality treatment of children with nephroblastoma]
Insights
Radiotherapy is crucial for treating advanced Wilms
Area of Science:
- Pediatric Oncology
- Radiation Oncology
- Nephroblastoma Research
Context:
- Wilms' tumor (nephroblastoma) is a significant pediatric malignancy.
- Multimodality treatment, including radiotherapy, is standard for advanced stages (III-IV).
- Understanding radiotherapy's role in survival and relapse is critical for optimizing treatment.
Purpose:
- To evaluate the efficacy and outcomes of radiotherapy in children with advanced Wilms' tumor.
- To analyze the impact of prognostic factors, including radiation dose and timing, on patient survival and relapse rates.
- To identify potential strategies for dose reduction without compromising survival.
Summary:
- A study of 225 children with stage III-IV Wilms' tumor assessed radiotherapy's role, with 97.3% receiving abdominal irradiation (mean 28 Gy).
- Relapses occurred in 34.2%, and 30.2% died; however, 35.1% survived >5 years.
- Delayed radiotherapy (>1 month post-surgery) increased abdominal relapse risk (21.9%). Reduced doses (≤21.6 Gy) showed no survival detriment, suggesting potential for dose optimization.
Impact:
- Findings support radiotherapy's vital role in advanced Wilms' tumor management.
- Highlights the importance of timely radiotherapy administration to minimize relapse.
- Suggests that reduced radiotherapy doses may be feasible for some patients, potentially minimizing long-term side effects.
Abstract:
The role of radiotherapy in multiple modality treatment of Wilms' tumor is evaluated in 225 children aged 3 months to 11.5 years (mean age 3.5 years) with stage III-IV. 184 (81.8%) patients presented with stage III, 93.7% with typical nephroblastoma. Intervention was combined with drug and radiotherapy in 99.6% patients. Exposure of the abdominal cavity in total focal doses of 10.5-50.2 Gy (mean dose 28 Gy) was carried out in 219 (97.3%) of 225 patients. Special attention is paid to the incidence of relapses, remote metastases, and survival of patients in relation to prognostic factors (sex, age, stage of tumor process, terms of exposure, and total focal doses). All patients were followed up for 2-203 months (median 32 months). During this period relapses and/or metastases were observed in 34.2% patients; 30.2% died because of disease progress. 35.1% children live without signs of disease for more than 5 years, 14.7% for more than 10 years. Relapses were more incident during the first year of treatment (in 65% children) and outside the exposed field (72.5% cases). 33.2% patients with stage III developed metastases after 1-49 months; the lungs were involved most often. Prolongation of the period between surgery and exposure of the abdominal cavity led to increase in the incidence of relapses in the abdominal cavity from 6.7% (up to 2 weeks) to 21.9% (more than 1 month), p = 0.02. Relapses were the most frequent in children aged over 4 years. This parameter virtually did not depend on the total focal dose. The absence of relationship between the incidence of local relapses and life span after exposure to a total focal dose of up to 21.6 Gy in comparison with higher doses recommends reduced doses for therapy without notable deterioration of the survival of patients with nephroblastoma.
More Related Videos
08:34Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers